Pseudomonas aeruginosa is a deadly opportunistic pathogen. It causes life-threatening infections in individuals with compromised immune systems, such as cancer patients undergoing chemotherapy or patients with cystic fibrosis. This bacterium is naturally resistant to many antimicrobials and with the overuse of antibiotics has become resistant to those it was once sensitive. Thus, there is a real need for new drugs and approaches to combat the myriad diseases caused by this pathogen. Computer aided drug design greatly facilitates the search for new antimicrobials. The various proteins that are essential for the pathogenesis of the organism can be the successful drug targets to facilitate the drug design processes. In this review we are discussing the various proteins involved in the pathogenesis of P. aeruginosa and their drugability. The identification of drug targets for a given human disease, whether it is mainly environmental or genetic in origin, depends on an understanding of the molecular chain of events that unfold in the disease process. Anatomic pathology, biochemistry, cellular physiology, and pharmacology constitute the main traditional approaches towards identifying potential therapeutic targets.